PharmiWeb.com - Global Pharma News & Resources
25-Jul-2019

At 4.5% CAGR, Active Pharmaceutical Ingredient Market Size Is Projected to Cross USD 225.2 Billion by 2025

An active pharmaceutical ingredient is a substance or a combination thereof used in a pharmaceutical product for providing direct access to the diagnosis, prevention, cure, or treatment of diseases or to have a direct impact in correcting, modifying, or restoring physiological functions in humans. Persistence Market Research has studied the global active pharmaceutical ingredients market in its report titled “Active Pharmaceutical Ingredients Market: Global Industry Analysis and Forecast, 2017 – 2025’’. The report includes revenue of the API manufacturers i.e. for both outsourced and in-house manufacturing. However, the report doesn’t consider API revenue that has not been mentioned herein.

Johnson Matthey, Siegfried, Almac, PolyPeptide Laboratories, AmbioPharm, Inc., Corden Pharma, Pepscan, BCN peptide, Provence Technologies Groups, SennChemicals AG, Avecia OligoMedicines, Santaris Pharma  - acquired by Roche in 2014, ST Pharm Oligo Center, Cepia Sanofi, Biospring, Pfizer CenterSource, Symbiotec Pharma Lab Pvt. Ltd., Gadea Grupo Farmacéutico, STEROID S.p.A., Dolder AG, Dalton Pharma Services, FarmaBios Spa, Dextra Laboratories Limited, GlycoSyn, Inalco Pharma, Sussex Research, Pfanstiehl, Inc., Noramco, Inc., Johnson Matthey, Siegfried, Rhodes Technologies, Ash Stevens, Fermion (public), FARMHISPANIA GROUP, Olon SpA, Lonza Group are some of the leading companies operating in the global active pharmaceutical ingredient market. Currently, many of the pharmaceutical companies are focused on outsourcing of API manufacturing to avoid large capital investments in setting up of API manufacturing facilities. This has accelerated the demand for CMOs in API manufacturing industry, which is dominated by small to medium manufacturers.

An active pharmaceutical ingredient is used in a finished pharmaceutical product (FPP), intended to carry certain pharmacological actions or otherwise have a direct effect in the diagnosis, cure, treatment, mitigation or prevention of various diseases, or in some cases in restoring, correcting or modifying human physiological functions. Sales of pharmaceutical ingredient are on the rise due to a substantial increase in high-potency API (HPAPI) and peptide API manufacturing.  A new study conducted by Persistence Market Research reveals that the US$ 151.9 Bn global active pharmaceutical ingredient market will grow to US$ 158.3 Bn by 2017 end, reflecting a Y-o-Y growth rate of 4.2%. This market is estimated to further increase to US$ 225.2 Bn, expanding at a CAGR of 4.5% over the forecast period (2016 – 2025)

For more information ask for sample report @ https://www.persistencemarketresearch.com/market-research/active-pharmaceutical-ingredient-market.asp

It is not surprising that there is a heavy regulatory oversight in a market as critical to human life as the active pharmaceutical ingredients market. A highly important section of the active pharmaceutical ingredients market report has specifically spoken about the major deals and regulations that pertain to API CDMO. It is followed by the drug pipeline analysis of Oligonucleotides, Peptides, Steroidal drugs, and High Potency API Drugs. The primary respondents by each region and their outlooks follow. The global active pharmaceutical ingredients market has been divided into five broad geographic regions viz. APAC, RoW, Europe, Latin America, and North America; each of which has its own section in the active pharmaceutical ingredients market report. The report provides the market value share and BPS analysis of the largest regional markets and also gives the market attractiveness on a country basis. Key trends and regulations that pertain to a specific region or country within that region complete this informative section.

The active pharmaceutical ingredients market report has a preface at the outset that is a brief glance at the active pharmaceutical ingredients market. It is closely related to (and followed by) the market definition as well as the taxonomy of the active pharmaceutical ingredients market. PMR analysts have studied the active pharmaceutical ingredients market for a period of eight years from 2017 to 2025 and have formed their opinions and recommendations based on current and future anticipated trends in the active pharmaceutical ingredients market. These have been detailed in the form of geographic regions and segments to target with a differentiating strategy to stand above all others in the active pharmaceutical ingredients market.

According to the report, small molecule API type segment holds promising investment opportunities for market participants on account of the numerous off-patent events incurred in the last five years coupled with a strong penetration of small scale manufacturers in Asia.  On the basis region, APAC’s API market was valued at US$ 61.4 Bn in 2016 and is projected to witness the highest CAGR of 5.1 % during the forecast period to reach a valuation of US$ 95.6 Bn. This is primarily owing to the leadership of China and India in SMEs as well as their strong distribution network in overseas markets especially in US, South Africa, and Europe. Asian pharmaceuticals CMOs are competing on the basis of cost and timeline for API manufacturing and are attracting U.S.-based pharmaceuticals companies that are willing to outsource manufacturing requirements. Meanwhile, Europe is projected to be the second fastest growing market for API and is expected to reach US$ 42.5 Bn by 2025-end. Manufacturers in Europe are prioritizing high-quality standards, advanced manufacturing installations, and high purity of intermediates (API).

Persistence Market Research Overview:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact:

Persistence Market Research

U.S. Sales Office:

305 Broadway, 7th Floor

New York City, NY 10007

United States

USA - Canada Toll-Free: 800-961-0353

Web Site: https://www.persistencemarketresearch.com

Email: sales@persistencemarketresearch.com

At 4.5% CAGR, Active Pharmaceutical Ingredient Market Size Is Projected to Cross USD 225.2 Billion by 2025

Editor Details

Last Updated: 30-Jul-2019